Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 5/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 4/20 | 0.36 |
| ▸ | MMP9 | P14780 | 4/20 | 0.36 |
| ▸ | MMP3 | P08254 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68540 | 0.79 | MMP2 (0.54) | ELANEGAAMEN1KMT2AALOX12 | |
| SCHEMBL4412405 | 0.72 | GAA (0.50) | ELANEGAAMEN1KMT2AALOX12 | |
| SCHEMBL8597730 | 0.71 | MMP2 (0.48) | ELANEGAAMEN1KMT2AALOX12 | |
| SCHEMBL267675 | 0.64 | ELANE (0.56) | ELANEGAAMEN1KMT2AALOX12 | |
| SCHEMBL265915 | 0.62 | GAA (0.41) | ELANEGAAMEN1KMT2AALOX12 | |
| SCHEMBL29819552 | 0.62 | LMNA (0.73) | ELANEMEN1KMT2AMMP2MMP9 | |
| SCHEMBL12997852 | 0.62 | CYP2C19 (0.71) | ELANEGAAMEN1KMT2AALOX12 | |
| SCHEMBL28822554 | 0.61 | GAA (0.51) | GAAMEN1KMT2AALOX12KDM4E | |
| SCHEMBL7481702 | 0.59 | MMP2 (0.64) | ELANEGAAMEN1KMT2AALOX12 | |
| SCHEMBL3633588 | 0.59 | KMT2A (0.37) | ELANEGAAMEN1KMT2AALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4734276-A | L-lysine pyruvate and l- histidine pyruvate and their use in therapy of tissue and mucosa damage | INSTITUT DR. ZIEGLER (CH) | 1988-03-29 | — | — | US | claimed |
| EP-4472606-A1 | COMPOSITIONS (III) | Symrise AG (DE) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023147852-A1 | COMPOSITIONS (III) | SYMRISE AG (DE) | 2023-08-10 | — | — | WO | disclosed |
| US-11535584-B2 | Homovanillinic acid ester, in particular for creating a warm and/or pungent sensation | SYMRISE AG (DE) | 2022-12-27 | — | — | US | disclosed |
| US-20220249535-A1 | COMPOSITIONS COMPRISING NICOTINAMIDE ADENINE DINUCLEOTIDE-RELATED COMPOUNDS AND USE THEREOF | REJUVENATION THERAPEUTICS (US) | 2022-08-11 | — | — | US | disclosed |
| US-20210040028-A1 | Homovanillinic acid ester, in particular for creating a warm and/or pungent sensation | SYMRISE AG (DE) | 2021-02-11 | — | — | US | disclosed |
| WO-2020206160-A1 | COMPOSITIONS COMPRISING NICOTINAMIDE ADENINE DINUCLEOTIDE-RELATED COMPOUNDS AND USE THEREOF | REJUVENATION THERAPEUTICS (US) | 2020-10-08 | — | — | WO | disclosed |
| US-20190276386-A1 | HOMOVANILLIC ESTER, MORE PARTICULARLY FOR ACHIEVING AN IMPRESSION OF HEAT AND/OR SPICINESS | BACKES MICHAEL (DE) | 2019-09-12 | — | — | US | disclosed |
| US-8354392-B2 | Drug-introduced photo-crosslinked hyaluronic acid derived gel | SEIKAGAKU CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20090118348-A1 | DRUG-INTRODUCED PHOTO-CROSSLINKED HYALURONIC ACID DERIVED GEL | SEIKAGAKU CORPORATION (JP) | 2009-05-07 | — | — | US | disclosed |
| WO-2008145733-A3 | NOVEL CHEMICAL COMPOUNDS, PRODUCTION THEREOF, AND USE THEREOF | UNIV LEIPZIG (DE) | 2009-05-07 | — | — | WO | disclosed |
| WO-2008145733-A2 | NOVEL CHEMICAL COMPOUNDS, PRODUCTION THEREOF, AND USE THEREOF | UNIVERSITÄT LEIPZIG (DE) | 2008-12-04 | — | — | WO | disclosed |
| EP-1905456-A1 | DRUG-CONTAINING PHOTOCROSSLINKED HYALURONIC ACID DERIVATIVE GEL | SEIKAGAKU CORPORATION (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-4734276-A | L-lysine pyruvate and l- histidine pyruvate and their use in therapy of tissue and mucosa damage | INSTITUT DR. ZIEGLER (CH) | 1988-03-29 | — | — | US | disclosed |
| US-4145444-A | 4-BUTYL-BENZOPHENONE | KAKEN CHEMICAL CO., LTD. (JP) | 1979-03-20 | — | — | US | disclosed |
| US-4124726-A | 2-FLUORO-4'-ALKYLBENZOPHENONE | KAKEN CHEMICAL CO., LTD. (JP) | 1978-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220249535-A1 | COMPOSITIONS COMPRISING NICOTINAMIDE ADENINE DINUCLEOTIDE-RELATED COMPOUNDS AND USE THEREOF | NAMPT, NQO1, NADK | ELANE 765/4885GAA 670/4885MEN1 3110/4885 |
| US-11535584-B2 | Homovanillinic acid ester, in particular for creating a warm and/or pungent sensation | TAS2R46, TAS2R50, TAS1R1 | ELANE 2188/4885GAA 1660/4885MEN1 2203/4885 |
| US-20190276386-A1 | HOMOVANILLIC ESTER, MORE PARTICULARLY FOR ACHIEVING AN IMPRESSION OF HEAT AND/OR SPICINESS | TAS2R4, HTR4, TAS2R20 | ELANE 4227/4885GAA 1971/4885MEN1 2502/4885 |
| US-20210040028-A1 | Homovanillinic acid ester, in particular for creating a warm and/or pungent sensation | TAS2R46, TAS2R50, TAS1R1 | ELANE 2188/4885GAA 1660/4885MEN1 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.